News

Zentalis shakes up PhIII plans in ovarian cancer; Halozyme’s deal with Acumen; Korro’s $117M private placement

Zentalis Pharma shakes up plans for Phase III in ovarian cancer: Zentalis announced Monday that it is no longer planning to test its lead candidate, azenosertib, in combination with chemotherapy in second-line platinum-sensitive ovarian cancer […]

No Picture
News

Rampart Health Bursts Out of Stealth Mode to Report 77% Disease Control in Metastatic Cancer from First-in-Human Phase 2 Trial (“Abscopal 5001”) of Multiplex Intra-tumoral Immunotherapy (MITI)

MITI was safe and well tolerated as a rapid outpatient treatment. Disease control (significant shrinkage or stabilization of cancer) seen in 77%. Untreated metastases regressed in 31% (Abscopal Effect). SAN DIEGO, Nov. 6, 2023 /PRNewswire/ […]

News

Ocean Pavilion returns to UN Climate Conference and Calls On Ocean Science to Lead Climate Solutions

A group of the world’s leading ocean scientific, philanthropic, and other stakeholder organizations, led by the Woods Hole Oceanographic Institution (WHOI) and Scripps Institution of Oceanography at the University of California San Diego, have come […]

News

Toragen, Inc. Announced Positive Safety Update from Cohort 1 of its Phase 1 Trial in Patients with Human Papillomavirus-Induced Cancer

SAN DIEGO–(BUSINESS WIRE)–Today, Toragen Inc., a San Diego-based clinical-stage biotechnology company focused on developing uniquely selective drugs targeting cancers caused by viruses, announced positive safety data from Cohort 1 of its Phase 1 trial of […]